, Volume 20, Issue 4, pp 243–251 | Cite as

Osteogenic Protein-1

A Review of its Utility in Spinal Applications
  • Andrew Brown
  • Gordon Stock
  • Alpesh A. Patel
  • Chukwuka Okafor
  • Alexander Vaccaro
Product Review


The potentially revolutionary effect that bone morphogenic proteins (BMPs) could have on orthopaedic surgery has fueled an exhaustive research effort that continues today. Upwards of 1.5 million bone-grafting operations take place in the US annually, with the anterior and posterior iliac crest being the most common donor site for autologous bone graft. Harvesting autologous bone graft, however, is not benign. It is postulated that a synthetic bone graft containing BMPs would possess the characteristics of autologous bone that allow new bone formation: osteogenesis, osteoinduction, and osteoconduction, without the negative repercussions related to bone harvesting. As a result of the ensuing research following their discovery some 40 years ago by Marshall Urist, the basic science behind BMPs has been largely uncovered. New information on BMPs now comes from clinical trials regarding their utility and efficacy in surgical applications. To date, BMPs have been studied in skeletal bone surgery throughout the body, and have been found to be particularly useful in surgical applications such as spinal arthrodesis. Osteogenic protein-1 (OP-1), or recombinant human BMP-7, is one subtype of BMPs that has shown particular potential in clinical trials. Pre-clinical and clinical studies have, thus far, garnered OP-1 a Humanitarian Device Exemption approval for spinal applications in the US. As clinical trials with larger patient numbers and longer clinical follow-up are completed, the usefulness of OP-1 as a bone graft substitute will be better elucidated.


Bone Formation Bone Graft Bone Morphogenic Protein Autologous Bone Graft Bone Graft Substitute 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors have no funding or financial conflicts of interests to disclose with commerially available products discussed within this paper.


  1. 1.
    Urist MR. Bone: formation by autoinduction. Science 1965; 150: 893–9PubMedCrossRefGoogle Scholar
  2. 2.
    Einhorn T. Clinical applications of rhBMPs: early experience and future development. J Bone Joint Surg 2003; 85-A Suppl. 3: 82–8Google Scholar
  3. 3.
    Arlington ED, Smith WJ, Chambers HG, et al. Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996 Aug; (329): 300–9Google Scholar
  4. 4.
    Sasso RC, Williams JI, Dimasi N, et al. Posteoperative drains at the donor sites of iliac-crest bone grafts: a prospective, randomized study of morbidity at the donor site in patients who had a traumatic injury of the spine. J Bone Joint Surg Am 1998; 80: 631–5PubMedCrossRefGoogle Scholar
  5. 5.
    Carlisle E, Fischgrund JS. Bone morphogenetic proteins for spinal fusion. Spine J 2005 Nov–Dec; 5Suppl. 6: 240–9SCrossRefGoogle Scholar
  6. 6.
    Muschler GF, Nakamoto C, Grauer JN. Bone healing and grafting. In: Vaccaro AR, editor. Orthopaedic knowledge update 8. Rosemont (IL): American Academy of Orthopaedic Surgeons, 2005: 29–37Google Scholar
  7. 7.
    Termaat MF, Den Boer FC, Bakker FC, et al. Current concepts review: bone morphogenic proteins. J Bone Joint Surg 2005 Jun; 87A(6): 1367–78CrossRefGoogle Scholar
  8. 8.
    Wozney JM, Rosen V, Celeste AJ, et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528–34PubMedCrossRefGoogle Scholar
  9. 9.
    Alden T, Varady P, Kallmes DF, et al. Bone morphogenic protein gene therapy. Spine 2002; 27(16S): S87–93PubMedCrossRefGoogle Scholar
  10. 10.
    ten Dijke P, Korchynskyi O, Valdimarsdottir G, et al. Controlling cell fate by bone morphogenic protein receptors. Mol Cell Endocrinol 2003 Dec 15; 211(1-2): 105–13CrossRefGoogle Scholar
  11. 11.
    ten Dijke P, Fu J, Schaap P, et al. Signal transduction of bone morphogenic proteins in osteoblast differentiation. J Bone Joint Surg 2003; 85-A Suppl. 3: 34–8Google Scholar
  12. 12.
    Ebara S, Nakayama K. Mechanism for the action of bone morphogenic proteins and regulation of their activity. Spine 2002; 27(16S): S10–5PubMedCrossRefGoogle Scholar
  13. 13.
    Valentin-Opran A, Wozney J, Csimma C, et al. Clinical evaluation of rhBMP-2. Clin Orthop Relat Res 2002; 3: 79–83Google Scholar
  14. 14.
    Seeherman H, Wozney J, Li R. BMP delivery systems. Spine 2002; 27: S16–23PubMedCrossRefGoogle Scholar
  15. 15.
    Bruder SP, Fox BS. Tissue engineering of bone: cell based strategies. Clin Orthop Relat Res 1999; 367: S68–83PubMedCrossRefGoogle Scholar
  16. 16.
    Johnson EE, Urist MR, Finerman GA. Bone morphogenetic protein augmentation grafting of resistant femoral nonunions: a preliminary report. Clin Orthop Relat Res 1988 May; (230): 257–65Google Scholar
  17. 17.
    Johnson EE, Urist MR, Finerman GA. Repair of segmental defects of the tibia with cancellous bone grafts augmented with human bone morphogenetic protein: a preliminary report. Clin Orthop Relat Res 1988 Nov; (236): 249–57Google Scholar
  18. 18.
    Johnson EE, Urist MR, Finerman GA. Distal metaphyseal tibial nonunion: deformity and bone loss treated by open reduction, internal fixation, and human bone morphogenetic protein (hBMP). Clin Orthop Relat Res 1990 Jan; (250): 234–40Google Scholar
  19. 19.
    Johnson EE, Urist MR, Finerman GA. Resistant nonunions and partial or complete segmental defects of long bones: treatment with implants of a composite of human bone morphogenetic protein (BMP) and autolyzed, antigen-extracted, allogeneic (AAA) bone. Clin Orthop Relat Res 1992 Apr; (277): 229–37Google Scholar
  20. 20.
    Harvinder S. Bone morphogenic proteins and spine surgery. Spine 2003; 28(15S): S64–73CrossRefGoogle Scholar
  21. 21.
    Geesink RG, Hoefnagels NH, Bulstra SK. Osteogenic activity of OP-1 bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 1999 Jul; 81(4): 710–8PubMedCrossRefGoogle Scholar
  22. 22.
    Friedlaender GE, Perry CR, Cole JD, et al. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. J Bone Joint Surg Am 2001; 83-A Suppl. 1 (Pt 2): S151–8Google Scholar
  23. 23.
    Vaccaro AR, Patel T, Fischgrund J, et al. A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine 2004 Sep 1;29(17): 1885–92PubMedCrossRefGoogle Scholar
  24. 24.
    Cook SD, Dalton JE, Tan EH, et al. In vivo evaluation of recombinant human osteogenic protein (rhOP-1) implants as a bone graft substitute for spinal fusions. Spine 1994 Aug 1; 19(15): 1655–63PubMedCrossRefGoogle Scholar
  25. 25.
    Paramore CG, Lauryssen C, Rauzzino MJ, et al. The safety of OP-1 for lumbar fusion with decompression: a canine study. Neurosurgery 1999 May; 44(5): 1151–5PubMedCrossRefGoogle Scholar
  26. 26.
    Patel TC, Erulkar JS, Grauer JN, et al. Osteogenic protein-1 overcomes the inhibitory effect of nicotine on posterolateral lumbar fusion. Spine 2001 Aug 1; 26(15): 1656–61PubMedCrossRefGoogle Scholar
  27. 27.
    Grauer JN, Patel TC, Erulkar JS, et al. 2000 Young Investigator Research Award winner. Evaluation of OP-1 as a graft substitute for intertransverse process lumbar fusion. Spine 2001 Jan 15; 26(2): 127–33PubMedCrossRefGoogle Scholar
  28. 28.
    Boden SD, Schimandle JH, Hutton WC. An experimental lumbar intertransverse process spinal fusion model: radiographic, histologic, and biomechanical healing characteristics. Spine 1995 Feb 15; 20(4): 412–20PubMedCrossRefGoogle Scholar
  29. 29.
    Magin MN, Delling G. Improved lumbar vertebral interbody fusion using rhOP-1: a comparison of autogenous bone graft, bovine hydroxylapatite (Bio-Oss), and BMP-7 (rhOP-1) in sheep. Spine 2001 Mar 1; 26(5): 469–78PubMedCrossRefGoogle Scholar
  30. 30.
    Cunningham BW, Shimamoto N, Sefter JC, et al. Osseointegration of autograft versus osteogenic protein-1 in posterolateral spinal arthrodesis: emphasis on the comparative mechanisms of bone induction. Spine J 2002 Jan–Feb; 2(1): 11–24PubMedCrossRefGoogle Scholar
  31. 31.
    Jenis LG, Wheeler D, Parazin SJ, et al. The effect of osteogenic protein-1 in instrumented and noninstrumented posterolateral fusion in rabbits. Spine J 2002 May–Jun; 2(3): 173–8PubMedCrossRefGoogle Scholar
  32. 32.
    Grauer JN, Vaccaro AR, Kato M, et al. Development of a New Zealand white rabbit model of spinal pseudarthrosis repair and evaluation of the potential role of OP-1 to overcome pseudarthrosis. Spine 2004 Jul 1; 29(13): 1405–12PubMedCrossRefGoogle Scholar
  33. 33.
    Sandhu HS, Khan SN. Animal models for preclinical assessment of bone morphogenetic proteins in the spine. Spine 2002 Aug 15; 27(16 Suppl. 1): S32–8PubMedCrossRefGoogle Scholar
  34. 34.
    Vaccaro AR, Anderson DG, Toth CA. Recombinant human osteogenic protein-1 bone morphogenetic protein-7) as an osteoinductive agent in spinal fusion. Spine 2002 Aug 15; 27(16 Suppl. 1): S59–65PubMedCrossRefGoogle Scholar
  35. 35.
    Poynton AR, Lane JM. Safety profile for the clinical use of bone morphogenetic proteins in the spine. Spine 2002 Aug 15; 27(16 Suppl. 1): S40–8PubMedCrossRefGoogle Scholar
  36. 36.
    Laursen M, Hoy K, Hansen ES, et al. Related articles, links recombinant bone morphogenetic protein-7 as an intracorporal bone growth stimulator in unstable thoracolumbar burst fractures in humans: preliminary results. Eur Spine J 1999; 8(6): 485–90PubMedCrossRefGoogle Scholar
  37. 37.
    Johnsson R, Stromqvist B, Aspenberg P. Randomized radiostereometric study comparing osteogenic protein-1 (BMP-7) and autograft bone in human noninstrumented posterolateral lumbar fusion: 2002 Volvo Award in clinical studies. Spine 2002 Dec 1; 27(23): 2654–61PubMedCrossRefGoogle Scholar
  38. 38.
    Vaccaro AR, Patel T, Fischgrund J, et al. A pilot safety and efficacy study of OP-1 putty (rhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J 2003 Oct; 12(5): 495–500. Epub 2003 Aug 8PubMedCrossRefGoogle Scholar
  39. 39.
    Vaccaro AR, Patel T, Fischgrund J, et al. A 2-year follow-up pilot study evaluating the safety and efficacy of op-1 putty (rhbmp-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J 2005 Sep; 14(7): 623–9. Epub 2005 Jan 26PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Andrew Brown
    • 1
  • Gordon Stock
    • 1
  • Alpesh A. Patel
    • 1
  • Chukwuka Okafor
    • 1
  • Alexander Vaccaro
    • 1
  1. 1.Department of Orthopaedic SurgeryThomas Jefferson University and the Rothman InstitutePhiladelphiaUSA

Personalised recommendations